Caitlin Raymond on ”The Plasma Chasers”
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at University of Wisconsin-Madison, shared on LinkedIn:
”I wrote a new piece this week about something I hadn’t encountered until I became an attending: the “plasma chaser.”
It’s not in ASFA guidelines, not in textbooks, and not something I ever saw in residency or fellowship. But it came up twice in two days, and it made me pause and think about how we make replacement-fluid decisions after recent procedures — and how much of that work happens in the gray space where physiology, experience, and uncertainty meet.
What I found, digging into the peer-reviewed survey data, is striking:
- 8.9% of clinicians still use albumin-only replacement one day after major surgery, a number much higher than I was expecting.
- Clinicians are split about 50/50 on using albumin vs plasma for replacement fluid a day following a minor procedure.
- For a patient scenario with no bleeding risk, 5.3% of clinicians will still use plasma, also higher than I was expecting.
There’s a story in those numbers — about risk perception, about judgment, and about how small, experience-driven practices evolve when formal guidance is limited.
In my blog post, I tried to unpack this… not to prescribe a standard, but to explore how we think through these nuanced decisions and why certain rituals persist in medicine. And also where a rational, physiologic framework can help us cut through the uncertainty.
If you’re interested in the intersection of transfusion medicine, clinical reasoning, and the quiet rituals we inherit in practice, you can read the full piece here.
Would love to hear how others approach post-procedure TPE decisions in their practice — especially where your institution aligns with (or diverges from) the survey data.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026